| Overview |
| bsm-61593r-rbitc-100ul |
| PRKD1/PKC mu Recombinant Antibody, RBITC Conjugated |
| WB |
| Human, Mouse, Rat |
| Specifications |
| RBITC |
| Rabbit |
| KLH conjugated synthetic peptide derived from human PKC mu |
| Recombinant |
| IgG |
| Lot dependent |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 5587 |
| Q15139 |
| Cytoplasm, Cell membrane |
| nPKC D1; nPKC mu; nPKCD1; nPKCmu; PKCM; PKCmu; PKD1; PRKCM; PRKD 1; Prkd1; Protein kinase C mu; Protein kinase C mu type; Serine/threonine protein kinase D1. |
| Serine/threonine-protein kinase that converts transient diacylglycerol (DAG) signals into prolonged physiological effects downstream of PKC, and is involved in the regulation of MAPK8/JNK1 and Ras signaling, Golgi membrane integrity and trafficking, cell survival through NF-kappa-B activation, cell migration, cell differentiation by mediating HDAC7 nuclear export, cell proliferation via MAPK1/3 (ERK1/2) signaling, and plays a role in cardiac hypertrophy, VEGFA-induced angiogenesis, genotoxic-induced apoptosis and flagellin-stimulated inflammatory response |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz